Baxter International $625 million acquisition of Claris Injectables

Overview:

• Baxter International has acquired Claris Injectables for $625 million.
• Claris is a subsidiary of Claris Lifesciences manufactures and markets a broad portfolio of essential medicines across multiple delivery systems and segments.
• Baxter International provides a broad portfolio of essential renal and hospital products, including home, acute and in-centre dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services.

Sam Duke - Editor